Zoetis Stock (ZTS)

XNYS Alert Compare

Health Care · Fundamental analysis

· How we analyze

Metrics from daily candles, as of Nov 20, 2026 · Extended universe

Figures in the price bar from TradingView (mostly trailing 12 months) · our fundamental analysis uses the fiscal year

Preset: moving averages 50 and 200 (on the daily chart the 50- and 200-day lines), plus volume. You can add further indicators in the chart yourself. Preset: moving averages 50 and 200 (on the daily chart the 50- and 200-day lines), plus volume. You can add further indicators in the chart yourself. Academy: 200-day line · RSI

About the company

Zoetis is an animal health company. It develops vaccines, medicines and diagnostics for pets such as dogs and cats and for livestock. It was spun off from Pfizer in 2013 and operates worldwide. As of Oct 13, 2026

Fact sheet (from the annual report) Pharmaceutical manufacturers · Parsippany, USA

The company operates in animal health and develops, manufactures and sells medicines, vaccines and diagnostics for animals. It is divided into a segment for the US market and an international segment. The products are aimed at companion animals such as dogs, cats and horses and at livestock such as cattle, pigs, poultry, fish and sheep. Companion animal products accounted for the majority of revenue in 2025. Companion animal products go mainly to veterinarians or veterinary distributors, and livestock products mainly to veterinarians and livestock producers. In October 2024 the group divested its portfolio of medicated feed additives.

Automatically summarized from SEC annual report (10-K, filed Feb 12, 2026) (website of the US Securities and Exchange Commission) · reviewed Oct 14, 2026

Price performance at a glance

Last 30 trading days
  • Today −2.1%
  • 7 days −5.6%
  • 30 days −0.6%
  • 1 year −31.7%
Day range (last trading day)
−0.4%Price at 7% of the range+5.0%
52-week range
−13.1%Price at 16% of the range+67.5%
Distance from the all-time high
−68.3%

Our own calculation from the exchange’s daily candles, as of Nov 20, 2026. “All-time” applies since the start of this series, not to the whole market. Changes in percent; the TradingView chart shows prices. “Today” = change of the last trading day versus the previous day. Not investment advice.

Fundamentals · Analysis method

Growth, margin, balance sheet, cash flow and dividend compared with the sector – with traffic lights and quality checks in the fundamental analysis. To the fundamental analysis

Fundamental analysis

Zoetis · Sector Health Care · amounts in USD

Source: SEC filings, As of Feb 12, 2026.

For you first Dividend

The dividend per share was never cut as far as our annual data goes (10 years in a row); free cash flow per share covers it 2.5x.

Years without a cut
at least 10
as far as the data goes
Growth per year (5 yrs)
+19.0%
dividend per share, average per year
Coverage by free cash flow
2.5x
covered from 1.0x

For you first Valuation

The P/E is below its own median of the 5 fiscal years before.

With a free account you can see how far – and the same for P/S and price/free cash flow, with the calculation. Sign up free

For you first Growth

How strongly revenue and earnings per share have grown over the years.

Check “Growth”
7 of 7
criteria with data met
Revenue per year (5 y)
+7.2%
EPS per year (5 y)
+12.0%

For you first Quality

How much of revenue remains and whether profit arrives as cash.

Check “Quality”
6 of 7
criteria with data met
Net margin
28.2%
Cash flow ÷ profit
1.09x
backed from 1.0 · 3 years: 1.09x

For you first Trading

The overview of this stock shows the trend by timeframe.

Quality checks

Four angles on the annual figures. Each check counts how many disclosed criteria are met – criteria without data do not count. The bars show where the company ranks on each figure among the stocks we cover and within its sector.

Fiscal year to Dec 31, 2025

Quality 6 of 7 met · 1 without data

  • met: Gross margin above 40% 71.8%
  • no data: Operating margin above 15% not stated in the SEC filings
  • met: Net margin above 10% 28.2%
  • met: Return on equity above 15% 80.2%
  • met: Free cash flow margin above 10% 24.1%
  • met: Profit in each of the last 5 fiscal years 5 of 5
  • met: Free cash flow positive in each of the last 3 fiscal years 3 of 3
  • not met: Equity ratio above 30% 21.5%
Gross margin

71.8% Fiscal year 2025

Rank 86 of 100: higher than 86% of 370 peers (All). strong.

Rank 81 of 100: higher than 81% of 49 peers (Sector). strong.

Median Health Care: 61.8%

Share of revenue left after the direct cost of the products sold.

Net margin

28.2% Fiscal year 2025

Rank 88 of 100: higher than 88% of 584 peers (All). strong.

Rank 87 of 100: higher than 87% of 63 peers (Sector). strong.

Median Health Care: 12.9%

Profit after all costs, interest and taxes divided by revenue.

Return on equity

80.2% Fiscal year 2025

Rank 97 of 100: higher than 97% of 544 peers (All). strong.

Rank 97 of 100: higher than 97% of 54 peers (Sector). strong.

Median Health Care: 12.8%

Net income divided by equity at fiscal year end.

Return on assets

17.3% Fiscal year 2025 (total assets at year end)

Rank 91 of 100: higher than 91% of 594 peers (All). strong.

Rank 91 of 100: higher than 91% of 63 peers (Sector). strong.

Median Health Care: 6.6%

Net income divided by total assets at fiscal year end.

Equity ratio

21.5% Fiscal year 2025

Rank 24 of 100: higher than 24% of 595 peers (All). weak.

Rank 18 of 100: higher than 18% of 63 peers (Sector). weak.

Median Health Care: 44.2%

Equity as a share of total assets. Usually low for banks.

Free cash flow margin

24.1% Fiscal year 2025

Rank 85 of 100: higher than 85% of 465 peers (All). strong.

Rank 84 of 100: higher than 84% of 61 peers (Sector). strong.

Median Health Care: 14.5%

Free cash flow divided by revenue.

Free cash flow

2.3B USD Fiscal year 2025

Operating cash flow minus capital expenditure on property and equipment.

Growth 7 of 7 met

  • met: Over 3 years, revenue grew by more than 5% per year +5.4%
  • met: Over 5 years, revenue grew by more than 5% per year +7.2%
  • met: Over 10 years, revenue grew by more than 5% per year +7.1%
  • met: Over 3 years, EPS grew by more than 5% per year +10.3%
  • met: Over 5 years, EPS grew by more than 5% per year +12.0%
  • met: Revenue rose in at least 4 of the last 5 fiscal years 5 of 5
  • met: Revenue rose in the last fiscal year +2.3%
Revenue growth 3 years

+5.4% per year

Rank 47 of 100: higher than 47% of 578 peers (All). medium.

Rank 52 of 100: higher than 52% of 62 peers (Sector). medium.

Median Health Care: +5.1%

Average growth per year over 3 fiscal years.

Revenue growth 5 years

+7.2% per year

Rank 41 of 100: higher than 41% of 549 peers (All). medium.

Rank 44 of 100: higher than 44% of 60 peers (Sector). medium.

Median Health Care: +7.8%

Average growth per year over 5 fiscal years.

Revenue growth 10 years

+7.1% per year

Rank 56 of 100: higher than 56% of 412 peers (All). medium.

Rank 31 of 100: higher than 31% of 50 peers (Sector). weak.

Median Health Care: +9.3%

Average growth per year over 10 fiscal years.

EPS growth 3 years

+10.3% per year

Rank 56 of 100: higher than 56% of 437 peers (All). medium.

Rank 62 of 100: higher than 62% of 54 peers (Sector). medium.

Median Health Care: +5.0%

Growth of earnings per share per year, adjusted for stock splits.

EPS growth 5 years

+12.0% per year

Rank 53 of 100: higher than 53% of 399 peers (All). medium.

Rank 65 of 100: higher than 65% of 47 peers (Sector). medium.

Median Health Care: +8.3%

Growth of earnings per share per year, adjusted for stock splits.

EPS growth 10 years

+24.4% per year

Rank 92 of 100: higher than 92% of 375 peers (All). strong.

Rank 92 of 100: higher than 92% of 46 peers (Sector). strong.

Median Health Care: +9.3%

Growth of earnings per share per year, adjusted for stock splits.

Dividend 6 of 6 met · 1 without data

  • met: Pays a dividend 2.03 USD
  • met: Payout ratio at most 60% of earnings 34%
  • met: Dividend paid in each of the last 5 fiscal years 5 of 5
  • met: Dividend per share never lowered in the last 5 fiscal years Dividend per share as filed with the SEC, including special dividends; a one-off higher prior year does not count as a cut. never
  • met: Dividend per share higher than 5 years ago +19.0%
  • met: Free cash flow per share covers the dividend 2.5x
  • no data: Dividends paid over the last 5 years covered by free cash flow dividends paid or free cash flow reported for fewer than 3 years
Payout ratio

34% Fiscal year 2025

Dividend per share divided by earnings per share.

Dividend growth 5 years

+19.0% per year

Rank 86 of 100: higher than 86% of 321 peers (All). strong.

Rank 92 of 100: higher than 92% of 31 peers (Sector). strong.

Median Health Care: +6.6%

Growth of the dividend per share per year.

Free cash flow coverage

2.5x Fiscal year 2025

Free cash flow per share divided by dividend per share. From 1x the dividend is covered.

Financial strength 5 of 6 met

  • met: Piotroski F-Score at least 7 of 9 8 of 9
  • not met: Long-term debt no higher than equity 2.71
  • met: Current assets cover current liabilities 3.03
  • met: Positive equity 3.3B USD
  • met: In 5 years, share count up by at most 5% −7.3%
  • met: Free cash flow positive in the last fiscal year 2.3B USD
Piotroski F-Score

8 of 9 Fiscal year 2025

Rank 88 of 100: higher than 88% of 310 peers (All). strong.

Rank 85 of 100: higher than 85% of 47 peers (Sector). strong.

Median Health Care: 6.0 of 9

Nine yes/no tests on profit, cash flow, debt, liquidity and efficiency compared with the prior year.

Debt / equity

2.71 at fiscal year end

Rank 7 of 100: lower than 7% of 486 peers (All). weak.

Rank 5 of 100: lower than 5% of 50 peers (Sector). weak.

Median Health Care: 0.66

Long-term financial debt divided by equity.

Liquidity (current ratio)

3.03 at fiscal year end

Rank 86 of 100: higher than 86% of 513 peers (All). strong.

Rank 83 of 100: higher than 83% of 63 peers (Sector). strong.

Median Health Care: 1.58

Current assets divided by current liabilities.

Change in share count

−7.3% in 5 years

Rank 67 of 100: lower than 67% of 507 peers (All). strong.

Rank 62 of 100: lower than 62% of 59 peers (Sector). medium.

Median Health Care: −4.3%

Change in diluted share count. Negative = share buybacks, positive = new shares.

The 9 criteria of the Piotroski F-Score
  • met: Profit in the last fiscal year (positive return on assets)
  • met: Positive operating cash flow
  • met: Return on assets higher than the prior year
  • met: Operating cash flow higher than net income
  • not met: Long-term debt relative to total assets fell
  • met: Liquidity (current assets / current liabilities) rose
  • met: No additional shares (diluted share count did not rise)
  • met: Gross margin higher than the prior year
  • met: Revenue relative to total assets higher than the prior year

Last fiscal year compared with the one before. Returns and revenue per total assets use total assets at the start of the year; leverage = long-term financial debt divided by total assets at year end; new shares via the average diluted share count.

Price-based criteria (P/E, dividend yield) are shown to signed-in users.

Computed automatically from SEC annual reports – not investment advice. Describes the reported figures; points are not a rating of the stock. Rank 0–100 against the 239 stocks we cover and against the sector (from 5 peers); the stronger side is always on the right.

In short

  • Light yellow: Revenue grew over 5 years (+7.2% per year), more slowly than the sector median.
  • Light green: Net income (total) grew over 5 years (+10.3% per year), at least as fast as the sector median; per share +12.0% per year.
  • Light green: Net margin 28.2%, above the sector median (13.9%).
  • Light red: Debt much higher than usual in the sector.
  • Light green: Profit in each of the last 10 fiscal years.

Summarized from the lights below. Describes the reported figures – not a recommendation to buy or sell.

RevenueNet income Net margin (below) in USD
  1. Fiscal year 2016 (Jan 1, 2016 – Dec 31, 2016): Revenue 4.9B USD · Net income 821.0M USD · Net margin 16.8%
  2. Fiscal year 2017 (Jan 1, 2017 – Dec 31, 2017): Revenue 5.3B USD · Net income 864.0M USD · Net margin 16.3%
  3. Fiscal year 2018 (Jan 1, 2018 – Dec 31, 2018): Revenue 5.8B USD · Net income 1.4B USD · Net margin 24.5%
  4. Fiscal year 2019 (Jan 1, 2019 – Dec 31, 2019): Revenue 6.3B USD · Net income 1.5B USD · Net margin 24.0%
  5. Fiscal year 2020 (Jan 1, 2020 – Dec 31, 2020): Revenue 6.7B USD · Net income 1.6B USD · Net margin 24.5%
  6. Fiscal year 2021 (Jan 1, 2021 – Dec 31, 2021): Revenue 7.8B USD · Net income 2.0B USD · Net margin 26.2%
  7. Fiscal year 2022 (Jan 1, 2022 – Dec 31, 2022): Revenue 8.1B USD · Net income 2.1B USD · Net margin 26.2%
  8. Fiscal year 2023 (Jan 1, 2023 – Dec 31, 2023): Revenue 8.5B USD · Net income 2.3B USD · Net margin 27.4%
  9. Fiscal year 2024 (Jan 1, 2024 – Dec 31, 2024): Revenue 9.3B USD · Net income 2.5B USD · Net margin 26.9%
  10. Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 9.5B USD · Net income 2.7B USD · Net margin 28.2%

Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 9.5B USD · Net income 2.7B USD · Net margin 28.2%

How has it gone since the last annual report?

Trailing 12 months and quarters

Revenue in the quarter to Sep 2026 −0.4% vs. the same quarter a year earlier.

Revenue 12 months vs. prior 12
+1.2%
12 months: 9.5B USD · Fiscal year 2025: +2.3%
Net margin 12 months
26.1%
Fiscal year 2025: 28.2%
Free cash flow margin 12 months
24.0%
Fiscal year 2025: 24.1%
More depth

Calculation of the 12 months to Sep 30, 2026

  • Revenue: fiscal year to Dec 31, 2025 9.5B USD + year to date to Sep 30, 2026 7.1B USD − same period a year earlier to Sep 30, 2025 7.1B USD = 9.5B USD
  • Net income: fiscal year to Dec 31, 2025 2.7B USD + year to date to Sep 30, 2026 1.9B USD − same period a year earlier to Sep 30, 2025 2.1B USD = 2.5B USD
  • Operating cash flow: fiscal year to Dec 31, 2025 2.9B USD + year to date to Sep 30, 2026 1.9B USD − same period a year earlier to Sep 30, 2025 2.0B USD = 2.8B USD
  • Capital expenditure: fiscal year to Dec 31, 2025 621.0M USD + year to date to Sep 30, 2026 334.0M USD − same period a year earlier to Sep 30, 2025 460.0M USD = 495.0M USD
By quarter (latest first, amounts in USD)
QuarterRevenuevs. year agoNet incomeMargin
Jul–Sep 262.4B−0.4%591.0M24.7%
Apr–Jun 262.5B+0.3%691.0M28.0%
Jan–Mar 26²2.3B+1.9%601.0M26.6%
Oct–Dec 25*2.4B+3.0%603.0M25.3%
Jul–Sep 252.4B+0.5%721.0M30.0%
Apr–Jun 252.5B+4.2%718.0M29.2%
Jan–Mar 252.2B+1.4%631.0M28.4%
Oct–Dec 24*2.3B+4.7%581.0M25.1%

Trailing 12 months = last fiscal year + the period since the start of the current fiscal year − the same period a year earlier, each from the first filing. P/E, PEG and the quality checks still use the last fiscal year.

Each quarter is compared with the same quarter a year earlier.

* derived: fiscal year minus the first 9 months.

² Year-ago quarter restated after a spin-off or divestiture – compared with the restated figure from the same report.

As of: 12 months to Sep 30, 2026, filed on Nov 5, 2026 · Source: SEC filings (10-Q, 10-K)

Does the profit arrive as cash?

Earnings quality

Profit is backed by cash; interest is well covered.

Cash flow ÷ profit
1.09x
backed from 1.0 · 3 years: 1.09x
Interest coverage
16.1x
well covered from 5 · EBIT, derived · 3 years: 14.7x
Tax rate
20.4%
for information only · 3 years: 20.4%
More depth

Calculation for fiscal year 2025

  • Operating cash flow 2.9B USD ÷ Net income 2.7B USD = 1.09x
  • EBIT, derived (profit before tax plus interest expense) 3.6B USD ÷ Interest expense 222.0M USD = 16.1x
  • Taxes 687.0M USD ÷ profit before tax 3.4B USD = 20.4%
By fiscal year
FYCash flow ÷ profitInterest coverageTax rate
20251.09x16.1x20.4%
20241.18x14.9x20.3%
20231.01x13.3x20.3%
20220.91x13.0x20.5%
20211.09x12.1x18.2%

How it is rated: cash flow ÷ profit from 1.0 “backed by cash”, below 0.8 “profit well above the cash coming in”; interest coverage from 5 “well covered”, below 2 “thinly covered”. The tax rate is only shown.

Cash flow ÷ profit uses group profit incl. minority interests, because cash flow also covers the whole group. Profit before tax as reported to the SEC, otherwise approximated. “3 years” = sums of the last three fiscal years – only if every year is reported and the figures have the same origin; for cash flow only with a profit in every year.

As of fiscal year 2025 · Source: SEC filings

How even were the last years?

Consistency

In 10 fiscal years no loss year and no year with lower revenue.

Loss years
0 of 10
net income below zero
Years with lower revenue
0 of 10
revenue below the prior year
Net margin range
12.0 percentage points
from 16.3% to 28.2%
Net margin by fiscal year
More depth
By fiscal year
FYRevenue vs. prior yearNet margin
2025+2.3%28.2%
2024+8.3%26.9%
2023+5.7%27.4%
2022+3.9%26.2%
2021+16.5%26.2%
2020+6.6%24.5%
2019+7.5%24.0%
2018+9.8%24.5%
2017+8.6%16.3%
2016+2.6%16.8%

Loss year: net income below zero. Lower revenue: revenue below the prior year. Range: highest minus lowest net margin; margins beyond ±200% do not count. No score – only the reported figures.

As of fiscal years 2016–2025 · Source: SEC filings

Figures over time

Where the money of a fiscal year goes and how margins, returns, balance sheet, cash flow and share count developed over up to 10 years. Each chart has one sentence saying what the trend shows.

Money flow in fiscal year 2025

Of 100 USD of revenue, 71.8 USD gross profit and 28.2 USD net income remained.

Money flow as a table
Fiscal year 2025, amounts in USD, share of revenue
ItemAmountof revenue
Revenue9.5B USD100.0%
Gross profit6.8B USD71.8%
Cost of revenue2.7B USD28.2%
Net income2.7B USD28.2%
Research & development698.0M USD7.4%
Interest expense222.0M USD2.3%
Taxes687.0M USD7.3%
Remaining costs & other2.5B USD26.6%

Taxes, interest and other items are not available separately in the SEC data; they are combined as the difference.

Margins

The net margin rose in 5 years from 24.5% to 28.2%.

Gross marginNet margin
  1. Fiscal year 2016: Gross margin 65.9% · Net margin 16.8%
  2. Fiscal year 2017: Gross margin 66.6% · Net margin 16.3%
  3. Fiscal year 2018: Gross margin 67.2% · Net margin 24.5%
  4. Fiscal year 2019: Gross margin 68.2% · Net margin 24.0%
  5. Fiscal year 2020: Gross margin 69.2% · Net margin 24.5%
  6. Fiscal year 2021: Gross margin 70.4% · Net margin 26.2%
  7. Fiscal year 2022: Gross margin 69.6% · Net margin 26.2%
  8. Fiscal year 2023: Gross margin 70.0% · Net margin 27.4%
  9. Fiscal year 2024: Gross margin 70.6% · Net margin 26.9%
  10. Fiscal year 2025: Gross margin 71.8% · Net margin 28.2%

Returns

Return on equity rose in 5 years from 43.5% to 80.2%.

Return on equityReturn on assets
  1. Fiscal year 2016: Return on equity 55.2% · Return on assets 10.7%
  2. Fiscal year 2017: Return on equity 48.8% · Return on assets 10.1%
  3. Fiscal year 2018: Return on equity 65.4% · Return on assets 13.3%
  4. Fiscal year 2019: Return on equity 55.4% · Return on assets 13.0%
  5. Fiscal year 2020: Return on equity 43.5% · Return on assets 12.0%
  6. Fiscal year 2021: Return on equity 44.8% · Return on assets 14.7%
  7. Fiscal year 2022: Return on equity 48.0% · Return on assets 14.2%
  8. Fiscal year 2023: Return on equity 46.9% · Return on assets 16.4%
  9. Fiscal year 2024: Return on equity 52.1% · Return on assets 17.5%
  10. Fiscal year 2025: Return on equity 80.2% · Return on assets 17.3%

Equity and long-term debt

The equity ratio fell in 5 years from 27.7% to 21.5%.

EquityLong-term debt in USD Long-term debt, depending on the filing, includes the current portion or leases.
  1. Fiscal year 2016: Equity 1.5B USD · Long-term debt 4.5B USD
  2. Fiscal year 2017: Equity 1.8B USD · Long-term debt 5.0B USD
  3. Fiscal year 2018: Equity 2.2B USD · Long-term debt 6.4B USD
  4. Fiscal year 2019: Equity 2.7B USD · Long-term debt 5.9B USD
  5. Fiscal year 2020: Equity 3.8B USD · Long-term debt 6.6B USD
  6. Fiscal year 2021: Equity 4.5B USD · Long-term debt 6.6B USD
  7. Fiscal year 2022: Equity 4.4B USD · Long-term debt 6.6B USD
  8. Fiscal year 2023: Equity 5.0B USD · Long-term debt 6.6B USD
  9. Fiscal year 2024: Equity 4.8B USD · Long-term debt 5.2B USD
  10. Fiscal year 2025: Equity 3.3B USD · Long-term debt 9.0B USD

Liquidity (current ratio)

The current ratio stayed roughly the same in 5 years (3.03).

Current ratio
  1. Fiscal year 2016: Current ratio 3.03
  2. Fiscal year 2017: Current ratio 3.85
  3. Fiscal year 2018: Current ratio 3.60
  4. Fiscal year 2019: Current ratio 2.63
  5. Fiscal year 2020: Current ratio 3.05
  6. Fiscal year 2021: Current ratio 3.86
  7. Fiscal year 2022: Current ratio 2.37
  8. Fiscal year 2023: Current ratio 3.36
  9. Fiscal year 2024: Current ratio 1.75
  10. Fiscal year 2025: Current ratio 3.03

Cash flow

Free cash flow rose in 5 years from 1.7B USD to 2.3B USD.

Operating cash flowCapital expenditureFree cash flow in USD
  1. Fiscal year 2016: Operating cash flow 713.0M USD · Capital expenditure 216.0M USD · Free cash flow 497.0M USD
  2. Fiscal year 2017: Operating cash flow 1.3B USD · Capital expenditure 224.0M USD · Free cash flow 1.1B USD
  3. Fiscal year 2018: Operating cash flow 1.8B USD · Capital expenditure 338.0M USD · Free cash flow 1.5B USD
  4. Fiscal year 2019: Operating cash flow 1.8B USD · Capital expenditure 460.0M USD · Free cash flow 1.3B USD
  5. Fiscal year 2020: Operating cash flow 2.1B USD · Capital expenditure 453.0M USD · Free cash flow 1.7B USD
  6. Fiscal year 2021: Operating cash flow 2.2B USD · Capital expenditure 477.0M USD · Free cash flow 1.7B USD
  7. Fiscal year 2022: Operating cash flow 1.9B USD · Capital expenditure 586.0M USD · Free cash flow 1.3B USD
  8. Fiscal year 2023: Operating cash flow 2.4B USD · Capital expenditure 732.0M USD · Free cash flow 1.6B USD
  9. Fiscal year 2024: Operating cash flow 3.0B USD · Capital expenditure 655.0M USD · Free cash flow 2.3B USD
  10. Fiscal year 2025: Operating cash flow 2.9B USD · Capital expenditure 621.0M USD · Free cash flow 2.3B USD

Share count

The share count fell in 5 years by 7.3% (mostly through share repurchases).

Diluted share count
  1. Fiscal year 2016: Diluted share count 498.2M
  2. Fiscal year 2017: Diluted share count 493.2M
  3. Fiscal year 2018: Diluted share count 486.9M
  4. Fiscal year 2019: Diluted share count 481.8M
  5. Fiscal year 2020: Diluted share count 478.6M
  6. Fiscal year 2021: Diluted share count 476.7M
  7. Fiscal year 2022: Diluted share count 470.4M
  8. Fiscal year 2023: Diluted share count 462.3M
  9. Fiscal year 2024: Diluted share count 454.8M
  10. Fiscal year 2025: Diluted share count 443.8M

From annual reports filed with the SEC (10-K, 20-F, 40-F) as first reported, share count adjusted for splits; obvious filing errors (e.g. wrong unit, outliers against both neighbouring years) are hidden. Describes the reported figures – not investment advice.

Metrics chart

Up to three metrics stacked over the same fiscal years – so you see at a glance whether they rise together or drift apart. Point at a year to read it in every panel.

Metrics, up to 3 – to switch, deselect one first

Premium Line of a second stock for comparison

Revenue

Revenue rose in 5 years from 6.7B USD to 9.5B USD.

ZTS in USD
  1. Fiscal year 2016: ZTS 4.9B USD
  2. Fiscal year 2017: ZTS 5.3B USD
  3. Fiscal year 2018: ZTS 5.8B USD
  4. Fiscal year 2019: ZTS 6.3B USD
  5. Fiscal year 2020: ZTS 6.7B USD
  6. Fiscal year 2021: ZTS 7.8B USD
  7. Fiscal year 2022: ZTS 8.1B USD
  8. Fiscal year 2023: ZTS 8.5B USD
  9. Fiscal year 2024: ZTS 9.3B USD
  10. Fiscal year 2025: ZTS 9.5B USD

Net margin

The net margin rose in 5 years from 24.5% to 28.2%.

ZTS Sector today 14.6% Mark in the latest year: today’s median of the Health Care sector as in the sector comparison (each latest fiscal year). We do not have earlier medians.
  1. Fiscal year 2016: ZTS 16.8%
  2. Fiscal year 2017: ZTS 16.3%
  3. Fiscal year 2018: ZTS 24.5%
  4. Fiscal year 2019: ZTS 24.0%
  5. Fiscal year 2020: ZTS 24.5%
  6. Fiscal year 2021: ZTS 26.2%
  7. Fiscal year 2022: ZTS 26.2%
  8. Fiscal year 2023: ZTS 27.4%
  9. Fiscal year 2024: ZTS 26.9%
  10. Fiscal year 2025: ZTS 28.2% · Sector today 14.6%

Free cash flow margin

The free cash flow margin stayed roughly the same in 5 years (24.1%).

ZTS Sector today 15.8%
  1. Fiscal year 2016: ZTS 10.2%
  2. Fiscal year 2017: ZTS 21.1%
  3. Fiscal year 2018: ZTS 24.9%
  4. Fiscal year 2019: ZTS 21.3%
  5. Fiscal year 2020: ZTS 25.1%
  6. Fiscal year 2021: ZTS 22.3%
  7. Fiscal year 2022: ZTS 16.4%
  8. Fiscal year 2023: ZTS 19.0%
  9. Fiscal year 2024: ZTS 24.8%
  10. Fiscal year 2025: ZTS 24.1% · Sector today 15.8%

Source: SEC filings, fiscal years up to Dec 31, 2025. The same figures as in the sections of this page, per fiscal year as first reported. Describes the reported figures – not investment advice.

How reliable is the dividend?

Dividend at a glance

The dividend per share was never cut as far as our annual data goes (10 years in a row); free cash flow per share covers it 2.5x.

Years without a cut
at least 10
as far as the data goes
Growth per year (5 yrs)
+19.0%
dividend per share, average per year
Coverage by free cash flow
2.5x
covered from 1.0x

You can see the dividend yield and shareholder yield (based on the price) with a free account. Sign up free

More depth

Calculation

  • Dividend per share: fiscal year 2020 0.85 USD → fiscal year 2025 2.03 USD = +19.0% per year
  • Free cash flow per share 5.14 USD ÷ dividend per share 2.03 USD = 2.5x

Years without a cut: in a row up to fiscal year 2025, dividend per share according to the SEC, adjusted for stock splits; only 1% less than the year before counts as a cut, also for variable dividends; a special dividend in the prior year does not. If the dividend per share falls while the total paid rises, the run ends as “unclear”. “At least” is shown only if our data ends earlier.

Shareholder yield: dividends paid plus share repurchases minus proceeds from new shares according to the cash flow statement of the last fiscal year, divided by today’s market value. Missing repurchases or new shares count as 0; without reported dividend or repurchase payments (among others for many stocks of the extended selection) there is no value. Describes the reported figures – not investment advice.

History, payout ratios and returns per year

As of fiscal year 2025 · Source: SEC filings

Valued higher or lower than usual?

Valuation against its own history

The P/E is below its own median of the 5 fiscal years before.

With a free account you can see how far – and the same for P/S and price/free cash flow, with the calculation. Sign up free

Source: SEC filings and our daily candles

Dividends and share repurchases

How much the company returns to its shareholders – as dividends or by repurchasing its own shares – and whether free cash flow supports it.

Dividend per share
2.03 USD · Fiscal year 2025
Dividend growth per year
3 y +14.6%5 y +19.0%10 y –
Payout ratio
of earnings 34% of free cash flow –
Share count over 5 years
−7.3% fewer shares – each share is a larger stake

Dividend per share

The dividend per share rose in 5 years from 0.85 USD to 2.03 USD.

Dividend per share USD per share Per share as filed with the SEC, including special dividends; obvious filing errors are hidden.
  1. Fiscal year 2016: Dividend per share 0.39 USD
  2. Fiscal year 2017: Dividend per share 0.44 USD
  3. Fiscal year 2018: Dividend per share 0.54 USD
  4. Fiscal year 2019: Dividend per share 0.69 USD
  5. Fiscal year 2020: Dividend per share 0.85 USD
  6. Fiscal year 2021: Dividend per share 1.08 USD
  7. Fiscal year 2022: Dividend per share 1.35 USD
  8. Fiscal year 2023: Dividend per share 1.56 USD
  9. Fiscal year 2024: Dividend per share 1.80 USD
  10. Fiscal year 2025: Dividend per share 2.03 USD

Payout ratios

The payout ratio rose in 5 years from 24.9% to 33.7%.

Payout ratio (earnings)
  1. Fiscal year 2016: Payout ratio (earnings) 23.6%
  2. Fiscal year 2017: Payout ratio (earnings) 25.2%
  3. Fiscal year 2018: Payout ratio (earnings) 18.5%
  4. Fiscal year 2019: Payout ratio (earnings) 22.3%
  5. Fiscal year 2020: Payout ratio (earnings) 24.9%
  6. Fiscal year 2021: Payout ratio (earnings) 25.2%
  7. Fiscal year 2022: Payout ratio (earnings) 30.1%
  8. Fiscal year 2023: Payout ratio (earnings) 30.7%
  9. Fiscal year 2024: Payout ratio (earnings) 32.8%
  10. Fiscal year 2025: Payout ratio (earnings) 33.7%

What goes back to shareholders

Over 5 years, 8.5B USD went back to shareholders through share repurchases; we do not have dividends paid as a total for 2021, 2022, 2023, 2024, 2025.

Dividends paidShare repurchasesNew shares issued (including employee plans)Free cash flow in USD
  1. Fiscal year 2016: Dividends paid not available · Share repurchases 300.0M USD · New shares issued (including employee plans) not available · Free cash flow 497.0M USD
  2. Fiscal year 2017: Dividends paid not available · Share repurchases 500.0M USD · New shares issued (including employee plans) not available · Free cash flow 1.1B USD
  3. Fiscal year 2018: Dividends paid not available · Share repurchases 698.0M USD · New shares issued (including employee plans) not available · Free cash flow 1.5B USD
  4. Fiscal year 2019: Dividends paid not available · Share repurchases 626.0M USD · New shares issued (including employee plans) not available · Free cash flow 1.3B USD
  5. Fiscal year 2020: Dividends paid not available · Share repurchases 250.0M USD · New shares issued (including employee plans) not available · Free cash flow 1.7B USD
  6. Fiscal year 2021: Dividends paid not available · Share repurchases 743.0M USD · New shares issued (including employee plans) not available · Free cash flow 1.7B USD
  7. Fiscal year 2022: Dividends paid not available · Share repurchases 1.6B USD · New shares issued (including employee plans) not available · Free cash flow 1.3B USD
  8. Fiscal year 2023: Dividends paid not available · Share repurchases 1.1B USD · New shares issued (including employee plans) not available · Free cash flow 1.6B USD
  9. Fiscal year 2024: Dividends paid not available · Share repurchases 1.9B USD · New shares issued (including employee plans) not available · Free cash flow 2.3B USD
  10. Fiscal year 2025: Dividends paid not available · Share repurchases 3.2B USD · New shares issued (including employee plans) not available · Free cash flow 2.3B USD

Dividends paid, repurchases and new shares issued from the cash flow statement of annual reports filed with the SEC (as first reported). Describes the reported figures – not investment advice.

Valuation over time

Price-based valuation (P/E, P/S, price/free cash flow and dividend yield per fiscal year, compared with its own average) for signed-in users.

Sector comparison

Zoetis next to 8 stocks of the sector Health Care we cover that are closest in revenue. Click a column header to sort the table.

Sector comparison ZTS, sector Health Care; last row: sector median
Symbol Revenue (FY) Growth 5 yrsGross marginOp. marginNet marginROEEquity ratioFCF marginPiotroski
AMGN Amgen 36.8B USD +7.6%67.2%24.7%21.0%89.1%9.6%22.0%7/9
MDT Medtronic 36.4B USD +3.8%65.0%17.8%13.2%9.7%53.2%14.9%7/9
GILD Gilead Sciences 29.4B USD +3.6%78.8%34.0%28.9%37.5%38.5%32.1%8/9
SYK Stryker Corporation 25.1B USD +11.8%64.0%19.5%12.9%14.5%46.9%17.1%6/9
DHR Danaher Corporation 24.6B USD +2.0%59.1%19.1%14.7%6.9%62.9%21.4%7/9
REGN Regeneron Pharmaceuticals 14.3B USD +11.0%–24.9%31.4%14.4%77.1%28.4%–
VRTX Vertex Pharmaceuticals 12.0B USD +14.1%86.2%34.8%32.9%21.2%72.8%26.6%–
ISRG Intuitive Surgical 10.1B USD +18.2%66.0%29.3%28.4%16.0%87.1%24.7%–
ZTS Zoetis this stock 9.5B USD +7.2%71.8%–28.2%80.2%21.5%24.1%8/9
Median of the sector 27 symbols 44.3B USD +8.4%67.9%18.0%14.6%14.3%38.4%15.8%7/9

Growth 5 yrs = revenue growth per year over 5 fiscal years · Op. margin = operating margin · ROE = return on equity · FCF = free cash flow · Piotroski = F-Score (only with all 9 criteria).

Compare with the closest peer in the sector ZTS next to ISRG – quality checks, metrics and depth side by side.

Figures of the last fiscal year from SEC annual reports (peers as of Nov 22, 2026). Median across all companies of the sector we cover (from 5 stocks; several share classes of one company count once). Signed-in users also see P/E, P/S and dividend yield in the comparison. Describes the reported figures – not investment advice.

Key figures with traffic lights

Each light follows a simple, disclosed rule. The comparison is with the sector median of all 26 symbols in the Health Care sector on our list (current members of the S&P 500 and other lists).

Revenue growth

Light yellow: below sector

+7.2% per year, last 5 years

Sector Health Care: median +8.5% (25 symbols)

What does this mean? Revenue: over 5 years it grew by 7.2% per year on average, but more slowly than the median company in the sector (+8.5%).

Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.

Net income (total)

Light green: above sector

+10.3% per year, last 5 years

Sector Health Care: median +5.5% (20 symbols)

per share: +12.0% per year (5 years, split-adjusted)

What does this mean? Total net income: over 5 years it grew by 10.3% per year on average – at least as fast as the median company in the sector (+5.5%).

Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.

Net margin

Light green: above sector

28.2% last fiscal year

Sector Health Care: median 13.9% (26 symbols)

What does this mean? Of every 100 USD in revenue, 28.23 USD remained as profit – at least as much as the median company in the sector (13.9%). Five years ago the margin was 24.5%.

Light rule: Green: at least the sector median (without a sector comparison: profit) · Yellow: profit, but below the median · Red: loss.

Debt / equity

Light red: much higher

2.51 latest balance sheet

Sector Health Care: median 0.66 (19 symbols)

What does this mean? For every 1 USD of equity there is 2.51 USD of financial debt – more than twice as much as the median company in the sector (0.66). More debt amplifies good and bad years alike.

Light rule: Green: at most the sector median · Yellow: up to twice the median · Red: more than twice · Gray: without a sector comparison.

Payout ratio

Light green: covered

34% Dividend / earnings per share

Sector Health Care: median 56% (16 symbols)

What does this mean? Of every 1 USD of earnings per share, 0.34 USD went to shareholders as a dividend. The rest stays in the company. Median company in the sector: 56%.

Light rule: Green: up to 60% of earnings · Yellow: up to 100% · Red: more than earnings or a dividend despite a loss · Gray for real estate (REITs). The sector median is for comparison only.

Profitable years

Light green: profit every year

10 of 10 fiscal years with a profit

What does this mean? In 10 of the last 10 fiscal years the bottom line showed a profit. There were no losses in this period.

Light rule: Green: profit in every year · Yellow: one loss year · Red: several loss years (at least 3 years needed).

Last fiscal year and 13F

Information, not a trading signal · Source: SEC EDGAR
Revenue (FY)
9.5B USD
Revenue vs. prior year
+2.3%
Net income (FY)
2.7B USD
Net income vs. prior year
+7.5%
EPS (FY)
6.02 USD
Superinvestors holding
3 of 26
Fiscal year to Dec 31, 2025 · 10-K filed Feb 12, 2026 · Balance sheet Sep 30, 2026 (filed Nov 5, 2026) · Price-based figures (P/E, P/S, dividend yield, market cap) only when logged in. · Values as first reported; debt = reported financial debt (US GAAP: long-term). Superinvestors: 26 tracked investors per 13F filing (as of quarter end, filed up to 45 days later); weight and change per investor in the card “Which superinvestors hold …?”.
All figures as a table
Fiscal years (amounts in USD, per share in USD)
YearEndRevenueNet income MarginEarnings per shareDividend per sharePayout
2025Dec 31, 2025 9.5B2.7B 28.2% 6.02 2.03 34%
2024Dec 31, 2024 9.3B2.5B 26.9% 5.47 1.80 33%
2023Dec 31, 2023 8.5B2.3B 27.4% 5.07 1.56 31%
2022Dec 31, 2022 8.1B2.1B 26.2% 4.49 1.35 30%
2021Dec 31, 2021 7.8B2.0B 26.2% 4.27 1.08 25%
2020Dec 31, 2020 6.7B1.6B 24.5% 3.42 0.85 25%
2019Dec 31, 2019 6.3B1.5B 24.0% 3.11 0.69 22%
2018Dec 31, 2018 5.8B1.4B 24.5% 2.93 0.54 18%
2017Dec 31, 2017 5.3B864.0M 16.3% 1.75 0.44 25%
2016Dec 31, 2016 4.9B821.0M 16.8% 1.65 0.39 24%
Quarters (amounts in USD, per share in USD)
QuarterEndRevenueNet income MarginEarnings per shareDividend per sharePayout
Q3/26Sep 30, 2026 2.4B591.0M 24.7% 1.44 0.00 0%
Q2/26Jun 30, 2026 2.5B691.0M 28.0% 1.65 0.53 32%
Q1/26Mar 31, 2026 2.3B601.0M 26.6% 1.42 0.53 37%
Q4/25*Dec 31, 2025 2.4B603.0M 25.3% – – –
Q3/25Sep 30, 2025 2.4B721.0M 30.0% 1.63 0.00 0%
Q2/25Jun 30, 2025 2.5B718.0M 29.2% 1.61 0.50 31%
Q1/25Mar 31, 2025 2.2B631.0M 28.4% 1.41 0.50 35%
Q4/24*Dec 31, 2024 2.3B581.0M 25.1% – – –
Q3/24Sep 30, 2024 2.4B682.0M 28.6% 1.50 0.00 0%
Q2/24Jun 30, 2024 2.4B624.0M 26.4% 1.37 0.43 32%
Q1/24Mar 31, 2024 2.2B599.0M 27.4% 1.31 0.43 33%
Q4/23*Dec 31, 2023 2.2B525.0M 23.7% – – –

* Q4 derived: fiscal year minus the 9-month value (EPS cannot be derived this way); may be distorted by restatements.

How we calculate: values as first reported to the SEC (later corrections are left out), a fixed order of reporting tags per figure, partial sums are never added up. Growth per year over 5 years (otherwise 3 years). Quarters are labeled by the calendar quarter in which they end.

Information only – does not affect the other analysis methods, not investment advice.

Insiders

All insider transactions
Insider purchases and sales on the market over 3, 6 and 12 months
PeriodPurchasesSalesNet
3 months $00 people $00 people $0
6 months $00 people $00 people $0
12 months $886.4K3 people $2.5M1 person −$1.7M

Latest transactions

  • May 13, 2026 Damelio Frank A Director Open-market purchase 6,650 shares · $501.3K · SEC
  • May 13, 2026 Bisaro Paul Director Open-market purchase 2,000 shares · $151.8K · SEC
  • May 11, 2026 Mccallister Michael B Director Open-market purchase 3,000 shares · $233.3K · SEC
  • Feb 17, 2026 Peck Kristin C Chief executive (CEO), Director Open-market sale · 10b5-1 plan 10,800 shares · $1.4M · SEC
  • Feb 17, 2026 Peck Kristin C Chief executive (CEO), Director Open-market sale · 10b5-1 plan 9,200 shares · $1.2M · SEC

Source: mandatory filings with the SEC (Form 4), open-market purchases and sales only. General information, not investment advice.

Which superinvestors hold Zoetis?

All superinvestor portfolios

3 of 26 tracked superinvestors report a position.

Superinvestors with a position in Zoetis, weight in each portfolio
InvestorWeight in portfoliovs. previous quarterAs of
Tom Gayner Markel Group 0.2% +542.5% increased Q3 2026
Renaissance Technologies 0.2% +18.3% increased Q3 2026
Bridgewater Associates 0.1% +254.9% increased Q3 2026

Sold out in the latest quarter: Soros Fund Management, Paul Tudor Jones.

Source: 13F filing with the US Securities and Exchange Commission, latest filing dated Nov 16, 2026. It shows positions at quarter end and is filed up to 45 days later – today the positions may be several months old. It covers only securities traded on US exchanges, without short positions; securities traded only abroad and cash are not included.

Trend score –

We do not calculate a trend score for symbols in the extended universe.

Volatility and trend strength

ADX 14 (trend strength)–
Price change 60 days–

ATR and moving averages as price values only when logged in.

More stocks from Health Care

All symbols in this sector

News

No recent news found. News is loaded automatically three times a day for trend stocks, symbols with a current Elliott setup and favorites.

Posts

No posts on ZTS yet – log in to join the discussion.

Posts are opinions of users and only visible after logging in. Community rules

Set alert: ZTS

Alerts with a free account: we send you an email as soon as the price moves above or below your level.

Checked after every data update: crypto hourly, stocks twice a day, precious metals every 4 hours on trading days, extended universe on weekdays after the close (daily candles) – not in real time.

↑ ↓ select · Enter open · Esc close